The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Express Scripts to add Zepbound to National Preferred Formulary
In clinical trials, treatment proved more effective than other therapies evaluated
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated
